Likewise, blocking SRC activity with short‐term treatment of the dual ABL/SRC tyrosine kinase inhibitor dasatinib led to improved glucose tolerance, and hepatic JNK1/2 ablation improved insulin sensitivity in models of diet‐induced obesity (DIO; Holzer et al, 2011; Vernia et al, 2014, 2016). The gene discussed is SRC; the disease is Obesity.